Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma
2014; Lippincott Williams & Wilkins; Volume: 193; Issue: 1 Linguagem: Inglês
10.1016/j.juro.2014.07.011
ISSN1527-3792
AutoresMatteo Santoni, Alessandro Conti, Camillo Porta, Giuseppe Procopio, Cora N. Sternberg, Umberto Basso, Ugo De Giorgi, Sergio Bracarda, Mimma Rizzo, Cinzia Ortega, Francesco Massari, Roberto Iacovelli, Lisa Derosa, Cristina Masini, Michèle Milella, Giuseppe Di Lorenzo, Francesco Atzori, Maria Pagano, Sebastiano Buti, Rocco De Vivo, Alessandra Mosca, Marta Rossi, Chiara Paglino, Elena Verzoni, Linda Cerbone, Giovanni Muzzonigro, Massimo Falconi, Rodolfo Montironi, Luciano Burattini, Daniele Santini, Stefano Cascinu,
Tópico(s)Cancer Genomics and Diagnostics
ResumoNo AccessJournal of UrologyAdult Urology1 Jan 2015Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma Matteo Santoni, Alessandro Conti, Camillo Porta, Giuseppe Procopio, Cora N. Sternberg, Umberto Basso, Ugo De Giorgi, Sergio Bracarda, Mimma Rizzo, Cinzia Ortega, Francesco Massari, Roberto Iacovelli, Lisa Derosa, Cristina Masini, Michele Milella, Giuseppe Di Lorenzo, Francesco Atzori, Maria Pagano, Sebastiano Buti, Rocco De Vivo, Alessandra Mosca, Marta Rossi, Chiara Paglino, Elena Verzoni, Linda Cerbone, Giovanni Muzzonigro, Massimo Falconi, Rodolfo Montironi, Luciano Burattini, Daniele Santini, and Stefano Cascinu Matteo SantoniMatteo Santoni Clinica di Oncologia Medica, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy , Alessandro ContiAlessandro Conti Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche, Clinica di Urologia, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy , Camillo PortaCamillo Porta Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy , Giuseppe ProcopioGiuseppe Procopio Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy , Cora N. SternbergCora N. Sternberg Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy , Umberto BassoUmberto Basso Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy , Ugo De GiorgiUgo De Giorgi IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-I.R.S.T., Meldola (FC), Italy , Sergio BracardaSergio Bracarda Department of Oncology, Istituto Toscano Tumori, Ospedale San Donato USL-8, Arezzo, Italy , Mimma RizzoMimma Rizzo Department of Medical Oncology, Cardarelli Hospital, Napoli, Italy , Cinzia OrtegaCinzia Ortega Oncology Foundation of Piedmont, Institute for Cancer Research and Treatment, Laboratory Medicine, Candiolo, Italy , Francesco MassariFrancesco Massari Medical Oncology, 'G.B. Rossi' Academic Hospital, University of Verona, Verona, Italy , Roberto IacovelliRoberto Iacovelli Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy , Lisa DerosaLisa Derosa UO Oncologia Medica 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori, Pisa, Italy , Cristina MasiniCristina Masini Oncology Division, Department of Oncology and Hematology, University of Modena e Reggio Emilia, Modena, Italy , Michele MilellaMichele Milella Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy , Giuseppe Di LorenzoGiuseppe Di Lorenzo Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, University Federico II, Napoli, Italy , Francesco AtzoriFrancesco Atzori Medical Oncology Unit, Azienda Ospedaliero Universitaria of Cagliari, Cagliari, Italy , Maria PaganoMaria Pagano Department of Oncology, Oncology Unit, Azienda Ospedaliera AsMN, Istituto di Ricovero e cura a carattere scientifico, Reggio Emilia, Italy , Sebastiano ButiSebastiano Buti Department of Oncology, University Hospital of Parma, Parma, Italy , Rocco De VivoRocco De Vivo Medical Oncology, S. Bortolo Hospital, Vicenza, Italy , Alessandra MoscaAlessandra Mosca Medical Oncology, Maggiore della Carità Hospital, University of Eastern Piedmont "A. Avogadro", Novara, Italy , Marta RossiMarta Rossi S.C. Oncologia Medica, Azienda Ospedaliera di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy , Chiara PaglinoChiara Paglino Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy , Elena VerzoniElena Verzoni Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy , Linda CerboneLinda Cerbone Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy , Giovanni MuzzonigroGiovanni Muzzonigro Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche, Clinica di Urologia, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy , Massimo FalconiMassimo Falconi Division of Pancreatic and Digestive Surgery, Università Politecnica delle Marche, Ancona, Italy , Rodolfo MontironiRodolfo Montironi Section of Pathological Anatomy, Università Politecnica delle Marche, School of Medicine, AOU Ospedali Riuniti, Ancona, Italy , Luciano BurattiniLuciano Burattini Clinica di Oncologia Medica, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy , Daniele SantiniDaniele Santini Oncologia Medica, University Campus Bio-Medico Roma, Rome, Italy , and Stefano CascinuStefano Cascinu Clinica di Oncologia Medica, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy View All Author Informationhttps://doi.org/10.1016/j.juro.2014.07.011AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Late recurrence of renal cell carcinoma is not a rare event. In this retrospective study we investigate the clinicopathological features and the outcome of patients treated with sorafenib, sunitinib and pazopanib for late relapsing renal cell carcinoma. Materials and Methods: Data were collected from 21 Italian centers involved in the treatment of metastatic renal cell carcinoma. Late relapse was defined as more than 5 years after initial radical nephrectomy. Results: A total of 2,490 patients were screened and 269 (11%) were included in the study. First line therapy was sunitinib in 190 patients (71%), sorafenib in 58 (21%) and pazopanib in 21 (8%). Median progression-free survival was 20.0 months for sunitinib (95% CI 17.0–25.1), and 14.1 months for sorafenib (95% CI 11.0–29.0) and pazopanib (95% CI 11.2–not reported). On multivariate analysis MSKCC score and metastases to lymph nodes, liver and brain were associated with worst overall survival, while pancreatic metastases were associated with longer survival. Furthermore, age, MSKCC score and brain metastases were associated with worst progression-free survival. Conclusions: Patients with late relapsing renal cell carcinoma seem to present a characteristic pattern of metastatic spread without showing significant differences in terms of progression-free survival among sorafenib, sunitinib and pazopanib. References 1 : Advanced renal cell carcinoma: current and emerging management strategies. Drugs2007; 67: 1257. Google Scholar 2 : Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol2013; 25: 273. Google Scholar 3 : Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol2005; 23: 832. Google Scholar 4 : A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol1995; 154: 28. Link, Google Scholar 5 : Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol2005; 174: 466. Link, Google Scholar 6 : Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol2001; 19: 1649. Google Scholar 7 : Renal cell carcinoma: long-term survival and late recurrence. J Urol1981; 126: 17. Link, Google Scholar 8 : Late recurrence of renal cell carcinoma after nephrectomy. Eur Urol1984; 10: 347. Google Scholar 9 : Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology2011; 77: 379. Google Scholar 10 : Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet2007; 370: 2103. Google Scholar 11 : Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol2008; 26: 5422. Google Scholar 12 : Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med2007; 356: 125. Google Scholar 13 : Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med2007; 356: 115. Google Scholar 14 : Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol2010; 28: 1061. Google Scholar 15 : Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet2011; 378: 1931. Google Scholar 16 : Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med2007; 356: 2271. Google Scholar 17 : Efficacy of everolimus in advanced renal cell carcinoma: a double-blind randomised placebo-controlled phase III trial. Lancet2008; 372: 449. Google Scholar 18 : Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treat Rev2014; 40: 271. Google Scholar 19 : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer2009; 45: 228. Google Scholar 20 : Multinomial goodness-of-fit tests for logistic regression models. Stat Med2008; 27: 4238. Google Scholar 21 : The impact of confounder selection criteria on effect estimation. Am J Epidemiol1989; 129: 125. Google Scholar 22 : Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol2013; 64: 472. Google Scholar 23 : Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol2012; 23: 973. Google Scholar 24 : Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?. J Urol2011; 185: 1611. Link, Google Scholar 25 : Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol2014; 65: 577. Google Scholar 26 : Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer2013; 4: 484. Google Scholar 27 : Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol2014; 65: 1086. Google Scholar 28 : Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med2013; 369: 22. Google Scholar © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byLaguna M (2018) Re: A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients with Metastatic Renal Cell CarcinomaJournal of Urology, VOL. 199, NO. 1, (23-25), Online publication date: 1-Jan-2018.Laguna M (2016) Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumJournal of Urology, VOL. 197, NO. 3 Part 1, (603-603), Online publication date: 1-Mar-2017.Steers W (2018) This Month in Adult UrologyJournal of Urology, VOL. 193, NO. 1, (1-3), Online publication date: 1-Jan-2015. Volume 193Issue 1January 2015Page: 41-47Supplementary Materials Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.Keywordssurvivalcarcinomaprotein-tyrosine kinasesrenal cellrecurrenceMetricsAuthor Information Matteo Santoni Clinica di Oncologia Medica, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy More articles by this author Alessandro Conti Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche, Clinica di Urologia, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy More articles by this author Camillo Porta Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy More articles by this author Giuseppe Procopio Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy More articles by this author Cora N. Sternberg Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy More articles by this author Umberto Basso Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy More articles by this author Ugo De Giorgi IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-I.R.S.T., Meldola (FC), Italy More articles by this author Sergio Bracarda Department of Oncology, Istituto Toscano Tumori, Ospedale San Donato USL-8, Arezzo, Italy More articles by this author Mimma Rizzo Department of Medical Oncology, Cardarelli Hospital, Napoli, Italy More articles by this author Cinzia Ortega Oncology Foundation of Piedmont, Institute for Cancer Research and Treatment, Laboratory Medicine, Candiolo, Italy More articles by this author Francesco Massari Medical Oncology, 'G.B. Rossi' Academic Hospital, University of Verona, Verona, Italy More articles by this author Roberto Iacovelli Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy More articles by this author Lisa Derosa UO Oncologia Medica 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori, Pisa, Italy More articles by this author Cristina Masini Oncology Division, Department of Oncology and Hematology, University of Modena e Reggio Emilia, Modena, Italy More articles by this author Michele Milella Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy More articles by this author Giuseppe Di Lorenzo Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, University Federico II, Napoli, Italy More articles by this author Francesco Atzori Medical Oncology Unit, Azienda Ospedaliero Universitaria of Cagliari, Cagliari, Italy More articles by this author Maria Pagano Department of Oncology, Oncology Unit, Azienda Ospedaliera AsMN, Istituto di Ricovero e cura a carattere scientifico, Reggio Emilia, Italy More articles by this author Sebastiano Buti Department of Oncology, University Hospital of Parma, Parma, Italy More articles by this author Rocco De Vivo Medical Oncology, S. Bortolo Hospital, Vicenza, Italy More articles by this author Alessandra Mosca Medical Oncology, Maggiore della Carità Hospital, University of Eastern Piedmont "A. Avogadro", Novara, Italy More articles by this author Marta Rossi S.C. Oncologia Medica, Azienda Ospedaliera di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy More articles by this author Chiara Paglino Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy More articles by this author Elena Verzoni Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy More articles by this author Linda Cerbone Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy More articles by this author Giovanni Muzzonigro Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche, Clinica di Urologia, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy More articles by this author Massimo Falconi Division of Pancreatic and Digestive Surgery, Università Politecnica delle Marche, Ancona, Italy More articles by this author Rodolfo Montironi Section of Pathological Anatomy, Università Politecnica delle Marche, School of Medicine, AOU Ospedali Riuniti, Ancona, Italy More articles by this author Luciano Burattini Clinica di Oncologia Medica, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy More articles by this author Daniele Santini Oncologia Medica, University Campus Bio-Medico Roma, Rome, Italy More articles by this author Stefano Cascinu Clinica di Oncologia Medica, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)